<DOC>
	<DOCNO>NCT00866606</DOCNO>
	<brief_summary>This study evaluate safety efficacy on-demand treatment BeneFIX Chinese hemophilia B subject .</brief_summary>
	<brief_title>Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Subjects equal 6 year age mild , moderate severe hemophilia B ( FIX activity : 5 % , 15 % , le 1 % , respectively ) Subjects previous exposure FIX replacement therapy If HIV positive , documented CD4 count 200/µL within 6 month study entry Diagnosed bleed disorder addition hemophilia B Current FIX inhibitor history FIX inhibitor ( define &gt; ULN report laboratory ) Subject history exposure FIX product ( previously untreated patient [ PUP ] ) Subject currently utilize primary FIX prophylaxis Subjects anticipate elective surgery may plan occur 6 month follow study entry Treated immunomodulatory therapy within 30 day prior study entry plan use duration study participation Participated another investigational drug device study within 30 day prior study entry plan participation duration study participation Subjects know hypersensitivity hamster protein Significant hepatic renal impairment ( ALT AST &gt; 5 x ULN , bilirubin &gt; 2 mg/dL serum creatinine &gt; 1.25 x ULN ) Prothrombin Time &gt; 1.5 x ULN Platelet count &lt; 80,000/µL Pregnant breastfeed woman Unwilling unable follow term protocol Any condition may compromise subject 's ability comply and/or perform studyrelated activity pose clinical contraindication study participation , opinion Investigator Sponsor</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>On-demand treatment</keyword>
	<keyword>Hemostatic efficacy</keyword>
	<keyword>Factor IX activity</keyword>
	<keyword>Factor IX recovery</keyword>
	<keyword>Factor IX inhibitor</keyword>
	<keyword>Chinese</keyword>
</DOC>